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ABSTRACT-A case report of triamterene bladder calculus is presented. Triamterene containing 
antihypertensiues should be used with caution in patients with predisposition to farm stones. 
Triamterene is a commonly used potassium- 
sparing natriuretic used alone (Dyrenium) or in 
combination with hydrochlorothiazide 
(Dyazide) to treat hypertension. Triamterene 
and its metabolites are excreted in the urine. 
Triamterene can be a cause of urolithiasis with 
an estimated incidence of 0.5 cases per 1,000 
persons taking the medication.’ Reported is a 
case of a bladder calculus in a Dyazide user, 
Stone analysis revealed a nidus of triamterene 
and its two major metabolites. The patient had 
continued symptoms of prostatism with ele- 
vated post-void residuals after cystolitholapaxy 
Incomplete emptying may have been a factor in 
the formation of his bladder calculus. Despite 
the rarity of triamterene urolithiasis, it is rec- 
ommended that Diazide users who may be at 
risk for stone formation be screened periodi- 
cally with an abdominal roentgenogram and 
urinalysis. 
Case Report 
A sixty-five-year-old white man presented 
with a five-month history of intermittent dis- 
comfort in the right and left lower abdominal 
quadrants which was not associated with void- 
ing. There was a history of intermittency, de- 
creased force of stream, and nocturia twice 
nightly. There was no past history of urinary 
tract infeetion, hematuria, or urolithiasis. He 
had a twenty-five-year history of hyperten- 
sion and was taking hydralazine hydrochloride 
(Apresoline), 15 mg PO q day, metoprolol 
tartrate (Lopressor), 15 mg PO q day, and 
Diazide I PÖ q da’y. Urinalysis was acéilular, 
and excretory urogram showed normal upper 
154 
urinary tracts; the calcification was in the blad- 
der (Fig. 1). The patient underwent cystolitho- 
lapaxy of a large, multifaceted bladder stone. 
Stone analysis was performed with 4.1 g of 
stone analyzed. It was composed of calcium 
oxalate monohydrate and uric acid surrounding 
a nidus of triamterene and its two major metab- 
olites, parahydroxytriamterene and parahy- 
droxytriamterene sulfate. The nidus of triam- 
terene represented 20 per cent of the total stone 
weight. On subsequent follow-up, obstructive 
voiding symptoms persisted as did elevated 
post-void residuals. Transurethral resection of 
the prostate was performed with an unre- 
markable postoperative course. The patient’s 
blood pressure has been managed without 
triamterene since his cystolitholapaxy and has 
had no further problems. 
FIGURE 1. Supìne plaìn film of pelvis showìng 
calcific shadow near rìght bladder wall, and con- 
firmed a.s large bladder calculus at cystoscopy. 
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Comment 
Triamterene is a diuretic which exerts its ef- 
fect on the distal renal tubule to inhibit the 
reabsorption of sodium in exchange for potas- 
sium and hydrogen ions. It is, therefore, a po- 
tassium-sparing natriuretic. It is most com- 
monly prescribed in combination with 
hydrochlorothiazide. Triamterene is rapidly 
metabolized to parahydroxytriamterene and 
then to parahydroxytriamterene sulfate. It is ex- 
creted in both bile and urine with urinary me- 
tabolites in much higher concentration than the 
parent compound. The t% for triamterene is 
one and one-half to two and one-half hours with 
urinary excretion diminishing within six to 
eight hours.2 
According to Louis C. Herring & Co., based 
on their extensive stone analysis experience, ap- 
proximately 1,450 stones containing some 
triamterene are being passed each year in the 
nation.’ It was also estimated that there are 3 
million people taking triamterene in one form 
or another giving an annual triamterene stone 
incidence of 0.5 per 1,000 persons taking the 
drug. The Herring Co. found 436 cases of 
triamterene urolithiasis in the eighteen-month 
period following the initial case report of triam- 
terene-induced nephrolithiasis in 1979, 3 
Though increased dosage of triamterene may be 
related to stone formation, many cases have 
been found on a dosage of only one Diazide per 
day (50 mg of triamterene). Triamterene stones 
are gold-mustard colored, can be smooth sur- 
faced but irregular in shape. If broken, they 
may show concentric lamellae. Triamterene 
also may be found in combination with calcium 
oxalate monohydrate and uric acid. It is almost 
never associated with calcium phosphate or 
magnesium ammonium phosphate.’ Some in- 
vestigators believe triamterene and its metabo- 
lites may catalyze calcium oxalate stone forma- 
tion.* There is no evidente, however, that the 
incidence of calcium oxalate stones is higher in 
triamterene users. 
The actual risk of stone formation while on 
triamterene therapy is unknown. As men- 
tioned, it has been estimated there is an inci- 
dence of 0.5 stones per 1,000 persons taking 
Dyazide. Frequency of urolithiasis in the 
United States has been estimated at 16.4 stones 
per 10,000 population which would be greater 
than the incidence of triamterene stone forma- 
tion in patients taking the medication5 Never- 
theless, it would seem prudent to recommend 
that those patients who are at risk for stone for- 
mation be screened at least once if they have 
been on chronic triamterene therapy. A simple 
abdominal plain film and urinalysis would 
seem to be appropriate. We believe our patient 
was at risk for bladder stone formation because 
of urinary stasis associated with his prostatism 
and high post-void residual. Patients with the 
diagnosis of triamterene stone formation, once 
stone free, should be cured by discontinuing the 
medication . 
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